Dh te R, Pellicer-Coeuret M, Belouet-Moreau C, Christoforov B, Vidal-Trecan G
Service de Santé Publique, Université René Descartes, Paris, France.
Clin Appl Thromb Hemost. 2001 Jan;7(1):16-20. doi: 10.1177/107602960100700104.
The aim of this study was to determine the prevalence of venous thromboembolism (VT) in current prophylactic practice with low-molecular-weight heparin (LMWH) among medical inpatients and to analyze associated risk factors for VT. A cross-sectional survey on five given days was conducted in the medical departments of a university hospital. The prevalence of prophylaxis and confirmed VT was measured. Risk markers for receiving high doses of LMWH and for VT under prophylaxis were assessed by logistic regression models. Of 1,194 inpatients, 1.4% suffered VT. The mean proportion of patients with LMWH prophylaxis was 24% (range: 4-64%). The prevalence of VT was higher among inpatients receiving prophylaxis than among those patients not receiving prophylaxis (3.5% vs. 0.7%, p = 0.002). Under prophylaxis, independent risk markers for thrombosis were history of vein thrombosis (odds ratio [OR]: 4.03; confidence interval [95%CI]: 1.04-15.62) and age (OR: 1.08; 95%CI: 1.01-1.15). Two factors were independently associated with the prescription of high doses of LMWH: obesity was positively associated (OR: 7.50; 95%CI: 2.97-18.92; p < 0.0001) and respiratory insufficiency was negatively associated. In medical departments, current prophylaxis practice leads to many patients being given LMWH. LMWH doses and other preventive measures should be adapted in high-risk inpatients.
本研究旨在确定在当前低分子量肝素(LMWH)预防性治疗实践中,内科住院患者静脉血栓栓塞症(VT)的患病率,并分析VT的相关危险因素。在一所大学医院的内科进行了为期五天的横断面调查。测量了预防性治疗和确诊VT的患病率。通过逻辑回归模型评估接受高剂量LMWH和预防性治疗下VT的风险标志物。在1194名住院患者中,1.4%发生了VT。接受LMWH预防性治疗的患者平均比例为24%(范围:4%-64%)。接受预防性治疗的住院患者中VT的患病率高于未接受预防性治疗的患者(3.5%对0.7%,p = 0.002)。在预防性治疗下,血栓形成的独立风险标志物是静脉血栓形成病史(比值比[OR]:4.03;置信区间[95%CI]:1.04-15.62)和年龄(OR:1.08;95%CI:1.01-1.15)。有两个因素与高剂量LMWH的处方独立相关:肥胖呈正相关(OR:7.50;95%CI:2.97-18.92;p < 0.0001),呼吸功能不全呈负相关。在内科,当前的预防性治疗实践导致许多患者接受LMWH治疗。对于高危住院患者,应调整LMWH剂量和其他预防措施。